NCT06358443Completed
The Long-term Effect of Daily Jarlsberg Cheese Intake in Patient With Osteopenia
The Long-term Effect on Bone Markers (BM) and Body Mineral Density (BMD) of Daily Jarlsberg Cheese Intake in Patient With Osteopenia
Source: ClinicalTrials.gov · Last updated 9 May 2025
Brief summary (registry, in English)
Aim: To estimate the effect of daily optimal efficacy dose (OED) of Jarlsberg cheese in patients with Osteopeni (OP). Study population: Post-menopausal women and men above 55 years of age in risk of Osteoporosis Treatment: Daily OED Jarlsberg cheese + vitamin D and Calcium tablets. Design: An open and one-armed observational study. Main variables: Bone Mineral Density (BMD), Bone turnover markers (BTMs), Osteocalcin and K2 vitameres. Study Procedure: Prior to inclusion in this study, all the patients have undergone 32 days of daily OED intake of Jarlsberg cheese + vitamin D and caicium tablets. Thid is the baseline of this observational study. The duration of this study is 12 months with clinical examination and bloodsampling after 6 and 12 months. Sample size: At least 16 patients will be included
- Status (registry)
- Completed
- Study type
- Interventional
- Enrollment
- 20 (actual)
- First submitted
- 5 Apr 2024
- Start date
- 3 Jun 2024
- Primary completion date
- 18 Oct 2024
- Lead sponsor
- Meddoc
- Diseases
- Osteoporosis
- NCT number
- NCT06358443
What you commit to
- Study type: Interventional
- Participants enrolled: 20
- From 3 Jun 2024 to the primary completion date, 18 Oct 2024
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Lab values
- • Diagnosed eating disorder.
- Serious gastrointestinal disorder.
- Serious liver or kidney disease. (GFR\<29 mL/min/1,73m2)
- Diabetes mellitus type I.
- Diabetes type II without sufficient control.
- Suffering from verified cancer.
- Under systemic treatment with corticosteroids the last 3 weeks before start of the trial treatment.
- Under active antiresorptive treatment or anabolic treatment.
- Participating in another clinical trial with pharmaceuticals the last six weeks before start of this trial treatment except from Jarlsberg cheese .
- Known milk protein allergy.
- Not able to understand information.
- Do not want or not able to give written consent to participate in the study.
Who the study is looking for
- Post-menopausal women and men passed the age of 55 years suffering from Osteopeni and had a daily Optimal Effective Dose of Jarlsberg Cheese the last 32 weeks prior to inclusion.
Age in the registry: - to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Skjetten Medical center Coordinator of this site? Confirm its status | Skjetten | Norway | Unknown status |
This page is information, not medical advice. Discuss any trial with your doctor.